pitavastatin
AssetAlso ULREA-PVS-NP
PLGA nanoparticles deliver pitavastatin to inhibit HMGCR and target inflammatory pathways associated with retinal degeneration.
- Stage
- Approved
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- 4
- Indications
- 55
- Trials
- 1
- Developer
Indications
4Cholesterol
Approved, accessdata.fda.gov, 10 Oct 2026
Heterozygous familial hypercholesterolemia
Approved, accessdata.fda.gov, 10 Oct 2026
Primary hyperlipidemia
Approved, accessdata.fda.gov, 10 Oct 2026
1 more
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials55
- Evidence for its targets4
- Competitors9
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.